The progress of prothrombin time measurement

Warfarin is the most widely used medicine for oral anticoagulant therapy (OAT). It inhibits the synthesis of coagulation factors II, VII, IX, and X in the liver and results in the production of inactive or partially active versions of these factors. Inactive coagulation factors interfere with prothr...

Full description

Bibliographic Details
Main Author: Juha Eero Horsti
Format: Article
Language:English
Published: MDPI AG 2009-12-01
Series:Hematology Reports
Subjects:
Online Access:http://www.pagepress.org/journals/index.php/hr/article/view/394
_version_ 1828046564232265728
author Juha Eero Horsti
author_facet Juha Eero Horsti
author_sort Juha Eero Horsti
collection DOAJ
description Warfarin is the most widely used medicine for oral anticoagulant therapy (OAT). It inhibits the synthesis of coagulation factors II, VII, IX, and X in the liver and results in the production of inactive or partially active versions of these factors. Inactive coagulation factors interfere with prothrombin time measurement (Quick and Owren PT) measuring the sum of coagulation activity and inhibition. The narrow therapeutic range here involves a danger of serious complications and the risk of bleeding or thrombosis. The new-generation PT method can measure coagulation activity and inhibition separately. This new technique promotes patient care and anticoagulant medication (warfarin, dicoumarol) based on coagulation activity in vivo. Both therapy and laboratory controls should be unquestionably accurate and based solely on in vivo coagulation activity. Inactive coagulation factors (inhibition) render measurement, calibration, and harmonization. The use of the new-generation PT method based on measurement of coagulation activity in vivo could develop vitamin K antagonist (VKA) therapy for the marked benefit of patients.
first_indexed 2024-04-10T18:27:34Z
format Article
id doaj.art-3d7429e8057c4379a64147d61e2ff9a5
institution Directory Open Access Journal
issn 2038-8322
2038-8330
language English
last_indexed 2024-04-10T18:27:34Z
publishDate 2009-12-01
publisher MDPI AG
record_format Article
series Hematology Reports
spelling doaj.art-3d7429e8057c4379a64147d61e2ff9a52023-02-02T05:04:48ZengMDPI AGHematology Reports2038-83222038-83302009-12-0112e19e1910.4081/hr.2009.e19998The progress of prothrombin time measurementJuha Eero HorstiWarfarin is the most widely used medicine for oral anticoagulant therapy (OAT). It inhibits the synthesis of coagulation factors II, VII, IX, and X in the liver and results in the production of inactive or partially active versions of these factors. Inactive coagulation factors interfere with prothrombin time measurement (Quick and Owren PT) measuring the sum of coagulation activity and inhibition. The narrow therapeutic range here involves a danger of serious complications and the risk of bleeding or thrombosis. The new-generation PT method can measure coagulation activity and inhibition separately. This new technique promotes patient care and anticoagulant medication (warfarin, dicoumarol) based on coagulation activity in vivo. Both therapy and laboratory controls should be unquestionably accurate and based solely on in vivo coagulation activity. Inactive coagulation factors (inhibition) render measurement, calibration, and harmonization. The use of the new-generation PT method based on measurement of coagulation activity in vivo could develop vitamin K antagonist (VKA) therapy for the marked benefit of patients.http://www.pagepress.org/journals/index.php/hr/article/view/394INRAnticoagulationWarfarin therapy
spellingShingle Juha Eero Horsti
The progress of prothrombin time measurement
Hematology Reports
INR
Anticoagulation
Warfarin therapy
title The progress of prothrombin time measurement
title_full The progress of prothrombin time measurement
title_fullStr The progress of prothrombin time measurement
title_full_unstemmed The progress of prothrombin time measurement
title_short The progress of prothrombin time measurement
title_sort progress of prothrombin time measurement
topic INR
Anticoagulation
Warfarin therapy
url http://www.pagepress.org/journals/index.php/hr/article/view/394
work_keys_str_mv AT juhaeerohorsti theprogressofprothrombintimemeasurement
AT juhaeerohorsti progressofprothrombintimemeasurement